The information hub for life sciences was designed to reduce drug counterfeiting and follows directives issued by governments worldwide requiring the serialization of drugs and commensurate compliant reporting. It significantly reduces the cost and risk of implementing required collaboration capabilities. The hub evolved from a pharmaceutical network developed by SAP and several large pharmaceutical wholesalers and manufacturers, including Boehringer Ingelheim and AmerisourceBergen. It uses a digital network built on SAP Cloud Platform and enables trading partners to exchange large amounts of serialization and associated traceability data.
“We are really excited to be a part of the new SAP product known as SAP Information Collaboration Hub for Life Sciences,” said Jeff Denton, senior director, AmerisourceBergen Global Secure Supply Chain. “We have utilized this tool in a number of pilots supporting our efforts to be compliant with the latest U.S. FDA regulations. It supports our need for a single point of entry or exit while sharing business transaction information with trading partners in a secure environment.”
SAP Information Collaboration Hub for Life Sciences initially will focus on traceability scenarios and then will expand to include a broader range of pharmaceutical supply chain processes, specifically those related to Identification of Medicinal Products (IDMP) regulatory compliance and those requiring the exchange of upstream batch data for multistep batch genealogy.
“SAP Information Collaboration Hub for Life Sciences, formerly known as the Pharma Network, turned out to be the right solution at the right time for Boehringer Ingelheim,” said Mary Mercado, head of Global IT Operations Services, Boehringer Ingelheim. “Connection to SAP Cloud Platform enables us to integrate third parties much more quickly into serialization processes in an agile supply chain and to vastly improve drug traceability.”
Visit the SAP News Center. Follow SAP on Twitter at @sapnews.
Stacy Ries, +1 (484) 619-0411, email@example.com, ET
Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to SAP are intended to identify such forward-looking statements. SAP undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. The factors that could affect SAP’s future financial results are discussed more fully in SAP’s filings with the U.S. Securities and Exchange Commission (“SEC”), including SAP’s most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.
© 2017 SAP SE. All rights reserved.
SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see http://www.sap.com/corporate-en/legal/copyright/index.epx#trademark for additional trademark information and notices.
Tags: AmerisourceBergen, Boehringer Ingelheim, SAP Cloud Platform, SAP Information Collaboration Hub for Life Sciences